Mathieu Vernier

Mathieu Vernier

Auto-generated profile, based on publicly available information

Mathieu Vernier

Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in eLife
Verified
Journal Article
Open access
SMShawn McGuirk
Shawn McGuirk
YAYannick Audet-Delage
Yannick Audet-Delage
MAMatthew G Annis
Matthew G Annis
YXYibo Xue
Yibo Xue
MVMathieu Vernier
Mathieu Vernier
JSJulie St-Pierre
Julie St-Pierre
Chemotherapy resistance is a critical barrier in cancer treatment. Metabolic adaptations have been shown to fuel therapy resistance; however, little is known regarding the generality of these changes and whether specific therapies elicit unique metabolic alterations. Using a combination of metabolomics, transcriptomics, and functional genomics, we show that two anthracyclines, doxorubicin and epirubicin, elicit distinct primary metabolic vulnerabilities in human breast cancer cells. Doxorubicin-resistant cells rely on glutamine to drive oxidative phosphorylation andde novoglutathione synthesis, while epirubicin-resistant cells display markedly increased bioenergetic capacity and mitochondrial ATP production. The dependence on these distinct metabolic adaptations is revealed by the increased sensitivity of doxorubicin-resistant cells and tumor xenografts to buthionine sulfoximine (BSO), a drug that interferes with glutathione synthesis, compared with epirubicin-resistant counterparts that are more sensitive to the biguanide phenformin. Overall, our work reveals that metabolic adaptations can vary with therapeutics and that these metabolic dependencies can be exploited as a targeted approach to treat chemotherapy-resistant breast cancer.

27 August 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
MVMathieu Vernier
Mathieu Vernier
SMShawn McGuirk
Shawn McGuirk
CDCatherine R. Dufour
Catherine R. Dufour
LWLiangxinyi Wan
Liangxinyi Wan
ÉAÉtienne Audet-Walsh
Étienne Audet-Walsh
VGVincent Giguere
Vincent Giguere
DNA methylation is implicated in the acquisition of malignant phenotypes, and the use of epigenetic modulating drugs is a promising anti-cancer therapeutic strategy. 5-aza-2’deoxycytidine (decitabine, 5-azadC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor with proven effectiveness against hematological malignancies and more recently triple-negative breast cancer (BC). Herein, genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNMT1 and the estrogen related receptor α (ERRα), a key transcriptional regulator of cellular metabolism. Mechanistically, DNMT1 promotes ERRα stability which in turn couples DNMT1 transcription with that of the methionine cycle and S-adenosylmethionine synthesis to drive DNA methylation. In vitro and in vivo investigation using a pre-clinical mouse model of BC demonstrated a clear therapeutic advantage for combined administration of the ERRα inhibitor C29 with 5-azadC. A large-scale bisulfite genomic sequencing analysis revealed specific methylation perturbations fostering the discovery that reversal of promoter hypermethylation and consequently derepression of the tumor suppressor gene, IRF4, is a factor underlying the observed BC suppressive effects. This work thus uncovers a critical role of ERRα in the crosstalk between transcriptional control of metabolism and epigenetics and illustrates the potential for targeting ERRα in combination with DNMT inhibitors for BC treatment and other epigenetics-driven malignancies.

22 March 2022 in Cell Reports
Verified
Journal Article
Open access
CDCatherine R. Dufour
Catherine R. Dufour
Charlotte ScholtesCharlotte Scholtes
Charlotte Scholtes
MYMing Yan
Ming Yan
YCYonghong Chen
Yonghong Chen
LHLingwei Han
Lingwei Han
VGVincent Giguere
Vincent Giguere
A growing number of studies support a direct role for nuclear mTOR in gene regulation and chromatin structure. Still, the scarcity of known chromatin-bound mTOR partners limits our understanding of how nuclear mTOR controls transcription. Herein, comprehensive mapping of the mTOR chromatin-bound interactome in both androgen-dependent and -independent cellular models of prostate cancer (PCa) identifies a conserved 67-protein interaction network enriched for chromatin modifiers, transcription factors, and SUMOylation machinery. SUMO2/3 and nuclear pore protein NUP210 are among the strongest interactors, while the androgen receptor (AR) is the dominant androgen-inducible mTOR partner. Further investigation reveals that NUP210 facilitates mTOR nuclear trafficking, that mTOR and AR form a functional transcriptional module with the nucleosome remodeling and deacetylase (NuRD) complex, and that androgens specify mTOR-SUMO2/3 promoter-enhancer association. This work identifies a vast network of mTOR-associated nuclear complexes advocating innovative molecular strategies to modulate mTOR-dependent gene regulation with conceivable implications for PCa and other diseases.

15 January 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
ÉAÉtienne Audet-Walsh
Étienne Audet-Walsh
MVMathieu Vernier
Mathieu Vernier
Benoit ViolletBenoit Viollet
Benoit Viollet
Editorial: AMPK and mTOR Beyond Signaling: Emerging Roles in Transcriptional Regulation

8 November 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
YMYounes Medkour
Younes Medkour
CDCatherine Rosa Dufour
Catherine Rosa Dufour
LHLingwei Han
Lingwei Han
PHPhillipe Hutton
Phillipe Hutton
MFMirna Farhat
Mirna Farhat
VGVincent Giguere
Vincent Giguere

3 April 2023
Verified
Other
Open access
ÉAÉtienne Audet-Walsh
Étienne Audet-Walsh
MVMathieu Vernier
Mathieu Vernier
TYTracey Yee
Tracey Yee
CLChloé Laflamme
Chloé Laflamme
SLSusan Li
Susan Li
VGVincent Giguere
Vincent Giguere
S1. ChIP-qPCR of SREBF1 in LNCaP cells after treatment with R1881, with infection of shRNA control (NTC; non-targeted control) or against SREBF1 (shSRE_1 and shSRE_2). S2. Protein expression of unprocessed SREBF1, with and without siRNAmediated knockdown (siSREBF1) in 22rv1 PCa cells. Tubulin is shown as a loading control. Phosphorylation status of S6, a downstream target of mTOR, is shown as a control of mTOR activation by R1881 (n=2). Supplemental Table 1. Human qRT-PCR primers. Supplemental Table 2. Human ChIP-qPCR primers.